Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Polaris Oligonucleotides
Laval, Québec, Canadapolarisoligos.com ↗
- Ownership
- Private
- Development stage
- Commercial
01
Overview
Polaris Oligonucleotides is a Canadian contract research organization founded in 2022 that specializes in high-quality, custom synthetic oligonucleotide services. The firm focuses on complex and chemically modified DNA/RNA oligos for academic, biotech, pharma, and diagnostic clients. It enables next-generation research by offering tailor-made solutions for challenging or novel nucleic acid chemistries[1][2].
- Modalities
- Synthetic oligonucleotideAntisense oligonucleotideRNA therapyDNA-based therapy
- Industry
- Drug Discovery Services
Beyond the preview
Go deeper on Polaris Oligonucleotides.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Polaris Oligonucleotides.